Tetraphase Pharmaceuticals Highlights Data at Upcoming American Society for Microbiology Microbe 2019 Annual Meeting - Seite 2

Presenter: Brian D. Johnston
Track: Antimicrobial Agents and Resistance
Sub-track: AAR09 – Pharmacological Studies of Investigational Agents Pre-NDA (Phase 2/3)
Date and time: Saturday, June 22 from 10:30 a.m. – 5:00 p.m. PT
Session type: Poster Presentation
Poster number: AAR-768

Poster title: Efficacy of TP-6076 in the Murine Thigh Infection Model With Acinetobacter baumannii
Presenter: Mark E. Pulse
Track: Antimicrobial Agents and Resistance
Sub-track: AAR08 – New Antimicrobial Agents (In Vitro and In Vivo Studies Prior to the Start of Clinical Therapy)
Date and time: Friday, June 21 from 10:30 a.m. – 5:00 p.m. PT
Session type: Poster Presentation
Poster number: AAR-787

Poster title: Pharmacokinetics and Efficacy of TP-6076 in the Murine Lung Infection Model With Acinetobacter baumannii
Presenter: William J. Weiss, M.S.
Track: Antimicrobial Agents and Resistance
Sub-track: AAR08 – New Antimicrobial Agents (In Vitro and In Vivo Studies Prior to the Start of Clinical Therapy)
Date and time: Friday, June 21 from 10:30 a.m. – 5:00 p.m. PT
Session type: Poster Presentation
Poster number: AAR-788

Symposium Presentation: Pharmacokinetics and Efficacy of TP-6076 in the Murine Lung Infection Model With Acinetobacter baumannii
Presenter: William J. Weiss, M.S.
Track: Antimicrobial Agents and Resistance
Sub-track: AAR09 – Pharmacological Studies of Investigational Agents Pre-NDA (Phase 2/3)
Date and time: Sunday, June 23 from 3:30 p.m. – 3:45 p.m. PT
Session: S339 – Pipeline Drugs to Treat Gram-negative Infections

Additional Activities:

• Tetraphase will host a XERAVA exhibit booth (#343) at ASM during exhibit hours.

About XERAVA^TM

XERAVA (eravacycline for injection) is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older. XERAVA was investigated for the treatment of cIAI as part of the Company's IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) Phase 3 program. In the first pivotal Phase 3 trial in patients with cIAI, twice-daily intravenous (IV) XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to ertapenem and was well-tolerated. In the second Phase 3 clinical trial in patients with cIAI, twice-daily IV XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to meropenem and was well-tolerated. In both trials, XERAVA achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates.